Morphic Medical, Inc.
GIDYL
OTC PK
| 03/31/2021 | 12/31/2020 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 79.16% | -64.40% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 42.50% | -40.63% | |||
| Operating Income | -42.50% | 40.63% | |||
| Income Before Tax | -30.24% | 49.89% | |||
| Income Tax Expenses | -- | 80.00% | |||
| Earnings from Continuing Operations | -29.60% | 49.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -29.60% | 49.71% | |||
| EBIT | -42.50% | 40.63% | |||
| EBITDA | -40.12% | 40.70% | |||
| EPS Basic | -- | -- | |||
| Normalized Basic EPS | 0.00% | 40.00% | |||
| EPS Diluted | -- | -- | |||
| Normalized Diluted EPS | 0.00% | 40.00% | |||
| Average Basic Shares Outstanding | -0.52% | 20.62% | |||
| Average Diluted Shares Outstanding | -0.52% | 20.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
